How Nordic Nanovector Stepped Back From The Abyss With APIM Merger
Picked Fellow Norwegian Firm After Multiple Talks
Executive Summary
Five months after its lead drug Betalutin failed for follicular lymphoma, Nordic Nanovector has secured its future by teaming up with Trondheim-based APIM and gained access to its mid-stage investigational therapy for ovarian cancer, sarcoma and glioblastoma.
You may also be interested in...
Deal Watch: BMS Backs Out Of UniQure Gene Therapy Collaboration
The gene therapy firm announced that Bristol terminated a collaboration started in 2015. Nona follows its recent alliance with Moderna with a second collaboration, this time with Dragonfly.
Nordic Nanovector To Restructure After Discontinuing Lymphoma Trial
The company still sees a potential future for Betalutin and hopes to partner the asset as it looks to focus on the rest of its pipeline.
BenevolentAI Still Bullish As CEO Shields Steps Down
BenevolentAI has added Merck KGaA to its list of partners but the UK firm is looking for a new CEO after Joanna Shields decided to leave as a major restructuring continues.